Skip to main content

Currently Skimming:

Summary
Pages 1-6

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... , is used in the majority of medical diagnostic imaging procedures in the United States, and secondarily on the use of HEU for research and test reactor fuel. This summary is organized around the four study charges provided by Congress and a fifth study charge negotiated between the National Academies and the study sponsor, the Department of Energy's National Nuclear Security Administration (DOE-NNSA)
From page 2...
... • Demand growth for Mo-99/Tc-99m in the United States over the next 5 years could range from 0 to 5 percent per year with the most likely growth rate in the range of 3 to 5 percent per year. • Demand growth for diagnostic imaging will likely continue over the long term as the U.S.
From page 3...
... Reliability of Mo-99 supply is likely to continue to be a serious problem for the United States in the early part of the next decade without new supply sources. • Conversion from HEU to LEU targets would remove policy uncertainties associated with the continued availability of HEU for use in Mo-99 production.
From page 4...
... Recommendations on additional steps that can be taken to encourage conversion are provided in response to the fifth study charge. The committee recommends that the RERTR Program increase its focus on eliminating HEU wastes that result from Mo-99 production facilities using U.S.-origin HEU by examining options to downblend this waste or encouraging its return to the United States.
From page 5...
... In fact, a 10 percent cost i ­ncrease for Mo-99 would provide very substantial resources for conversion and would have a negligible impact on the cost of common diagnostic imaging procedures. The committee has insufficient information regarding ­ potential conversion costs for the South African producer Nuclear T ­ echnology Products Radioisotopes.
From page 6...
... • Food and Drug Administration (FDA) : Work with industry and DOE's technical experts to ensure that there is a common understanding of LEU-based production of Mo-99 from a regulatory perspective, and also that there is a good understanding of likely FDA requirements for obtaining regulatory approvals for the use of this isotope in radiopharmaceuticals.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.